Stockscreener 앱 받기
32.64
1.33%
0.43
시간 외 거래:
32.64
전일 마감가:
$32.21
열려 있는:
$32.7
하루 거래량:
472.38K
Relative Volume:
0.91
시가총액:
$1.58B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+3.88%
1개월 성능:
+6.35%
6개월 성능:
+133.98%
1년 성능:
+174.98%
1일 변동 폭
$31.50
$33.62
1주일 범위
$31.00
$33.89
52주 변동 폭
$5.485
$36.51
Oruka Therapeutics Inc Stock (ORKA) Company Profile
명칭
Oruka Therapeutics Inc
전화
650-606-7910
주소
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
32.64 | 1.56B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Piper Sandler | Overweight |
| 2025-11-13 | 개시 | Jefferies | Buy |
| 2025-10-27 | 개시 | Guggenheim | Buy |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-05-22 | 개시 | BTIG Research | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-10-11 | 개시 | Stifel | Buy |
| 2024-10-07 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | Leerink Partners | Outperform |
| 2024-09-16 | 개시 | TD Cowen | Buy |
| 2024-09-13 | 개시 | Jefferies | Buy |
| 2018-02-27 | 개시 | Ascendiant Capital Markets | Buy |
| 2013-10-09 | 개시 | Dawson James | Buy |
모두보기
Oruka Therapeutics Inc 주식(ORKA)의 최신 뉴스
Candriam S.C.A. Buys 250,296 Shares of Oruka Therapeutics, Inc. $ORKA - MarketBeat
Will Oruka Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Action & Accurate Buy Signal Alerts - mfd.ru
Is Oruka Therapeutics Inc. stock a contrarian buy2025 Investor Takeaways & Expert Curated Trade Setup Alerts - mfd.ru
Oruka Therapeutics to Participate in Multiple Upcoming Conferences - The Manila Times
Oruka Therapeutics präsentiert sich auf mehreren internationalen Biotech-Konferenzen - Longbridge
Dow Update: What is Oruka Therapeutics Incs book value per share2025 Retail Activity & Verified Swing Trading Watchlists - baoquankhu1.vn
Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy - TipRanks
How Oruka Therapeutics Inc. stock performs in high volatility marketsJuly 2025 EndofMonth & Long Hold Capital Preservation Plans - mfd.ru
Investment Review: Will Oruka Therapeutics Inc outperform tech stocks2025 Risk Factors & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Down 31.3% in January - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Oruka Therapeutics, Inc. (ORKA) Stock Report: Biotechnology Pioneer Poised for 57.87% Upside - DirectorsTalk Interviews
Portfolio Update: Is Global Blue Group Holding AG Equity Warrant stock a top performer YTDQuarterly Growth Report & Long Hold Capital Preservation Plans - baoquankhu1.vn
How cyclical is Oruka Therapeutics Incs revenue streamWeekly Investment Recap & Safe Capital Growth Stock Tips - baoquankhu1.vn
How Early ORKA-002 Dosing Data At Oruka Therapeutics (ORKA) Has Changed Its Investment Story - simplywall.st
H.C. Wainwright Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $40 - 富途牛牛
Oruka Therapeutics (NASDAQ:ORKA) Shares Gap DownHere's What Happened - MarketBeat
Market Outlook: Does Oruka Therapeutics Inc stock have upside surprise potential2025 Market Overview & Stock Portfolio Risk Management - baoquankhu1.vn
Fed Meeting: Will Oruka Therapeutics Inc outperform tech stocksJuly 2025 Reactions & Entry Point Confirmation Signals - baoquankhu1.vn
RSI Check: Can GLPG outperform under higher oil pricesJuly 2025 Highlights & Daily Market Momentum Tracking - baoquankhu1.vn
Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week HighWhat's Next? - MarketBeat
Gains Report: Will Oruka Therapeutics Inc benefit from AI trendsGold Moves & Reliable Momentum Entry Alerts - baoquankhu1.vn
Aug Opening: Will ARTV outperform the market in YEAR2025 Major Catalysts & Low Drawdown Trading Techniques - baoquankhu1.vn
Assessing Oruka Therapeutics (ORKA) Valuation After Encouraging ORKA 002 Phase 1 Trial Results - Sahm
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Update - MarketBeat
Joana Goncalves Sells 7,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock - MarketBeat
Oruka Therapeutics stock hits 52-week high at 32.65 USD By Investing.com - Investing.com Nigeria
Oruka Therapeutics (ORKA) Is Up 23.1% After Extended-Dosing IL-17 Data for ORKA-002What's Changed - Sahm
Oruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month HighHere's Why - MarketBeat
Oruka Therapeutics stock hits 52-week high at 32.65 USD - Investing.com
Pullback Watch: What is Oruka Therapeutics Incs book value per shareJuly 2025 Review & Fast Entry Momentum Alerts - baoquankhu1.vn
Oruka Therapeutics (ORKA) Price Target Increased by 12.54% to 56.44 - Nasdaq
Clear Street raises Oruka Therapeutics stock price target on promising drug data - Investing.com Canada
Oruka reports positive interim data for ORKA-002 in Phase 1 trial - Investing.com Nigeria
Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001 - Dermatology Times
BTIG Research Issues Positive Forecast for Oruka Therapeutics (NASDAQ:ORKA) Stock Price - MarketBeat
Oruka reports positive interim data for ORKA-002 in Phase 1 trial By Investing.com - Investing.com South Africa
Oruka Therapeutics, Inc. Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of Everlong-B Trial of ORKA-001 - marketscreener.com
Earnings Risk: Is OPFI affected by consumer sentimentJuly 2025 Highlights & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Oruka Therapeutics (NASDAQ:ORKA) Earns Buy Rating from Analysts at UBS Group - Defense World
Aug Outlook: Why Oruka Therapeutics Inc. stock is favored by top institutions2025 Retail Activity & Real-Time Volume Spike Alerts - Улправда
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: Unpacking a 97.60% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Oruka Therapeutics (NASDAQ:ORKA) Rating Increased to Strong-Buy at UBS Group - MarketBeat
ORKA-001 psoriasis trial: Fresh phase 2 update and what it means for investors - MSN
Does UBS’s New Coverage Reframe Oruka Therapeutics (ORKA) as a Peptide Platform, Not Just a Biotech? - Sahm
How buybacks impact Oruka Therapeutics Inc. stock valueJuly 2025 Macro Moves & Risk Controlled Swing Alerts - ulpravda.ru
Can Oruka Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Trade Ideas & Reliable Breakout Stock Forecasts - Улправда
Will Oruka Therapeutics Inc. (HQ1) stock top growth indexes2025 Market WrapUp & Precise Swing Trade Entry Alerts - ulpravda.ru
Why Oruka Therapeutics Inc. stock is a must watch in 2025Earnings Beat & AI Powered Market Entry Strategies - Улправда
Is Oruka Therapeutics Inc. (HQ1) stock undervalued historicallyJuly 2025 Technicals & Reliable Price Breakout Alerts - Улправда
Oruka Therapeutics Inc (ORKA) 재무 분석
Oruka Therapeutics Inc (ORKA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Oruka Therapeutics Inc 주식 (ORKA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Goncalves Joana | Chief Medical Officer |
Jan 15 '26 |
Sale |
31.81 |
7,000 |
222,704 |
1,518 |
| Sandler Laura Lee | Chief Operating Officer |
Jan 02 '26 |
Option Exercise |
7.80 |
5,000 |
39,000 |
218,084 |
| Sandler Laura Lee | Chief Operating Officer |
Jan 02 '26 |
Sale |
28.52 |
13,000 |
370,795 |
205,084 |
1.24%
0.19%
자본화:
|
볼륨(24시간):